The ADC Supply Squeeze
May 2026
Announced capacity is not staffed capacity. The supply-side read of who can actually make an ADC, where the chain chokes, and the talent gap nobody has hired for. The supply-side companion to The State of ADCs 2026. The boom is real and it is booked. The constraint is no longer the science or the capital. It is whether these molecules can be made at the scale the pipeline now demands, and underneath that, whether anyone can hire the people to run the lines. This report measures that constraint, and finds the binding limit is specialist talent the announced build-out has not yet hired.
Who reads this
Read by CDMO strategy and BD leaders, CMC and manufacturing leadership at ADC developers, and investors pricing capacity risk, across the US, UK, EU, and Asia.
Built from a single reconciled evidence base, primary sources only.
Authored by
Byron Fitzgerald, Founder, ProGen Search
What This Report Covers
Maps the ADC supply side across nine sections: who can actually manufacture a complete conjugate end to end, where the four-node chain chokes, the capacity gap quantified, the talent bottleneck underneath it, and what policy and geography are doing to the map. Written for anyone making capacity, partner-selection, or capital decisions against a demand wave that is already booked.
Built on one method no competitor can copy. Every announced ADC capacity expansion from 2022 to May 2026 was tested against a single question: can matching, co-located hiring actually be confirmed at that site. That is what separates announced capacity from staffed capacity, and it is the basis for the report's central finding. Every figure traces to a primary source and carries its verification verdict. Where a fact can still move, the report says so on the page.
Buy this report
From
$1,495
Three licence tiers for individuals, teams, and institutions.
Individual
Single reader
$1,495
Enterprise
One operating company
$5,995
Investor & Bank Licence
Banks and institutional investors
$14,995
Chapters
The Demand Wave
Six marketed ADCs each cleared a billion dollars in 2024. The one listed pure-play CDMO files a backlog up more than 70% year on year. Demand is outrunning operational supply, and it is not a forecast.
Who Can Manufacture
The set of contract manufacturers that can make a complete ADC end to end, under full containment, under one roof, is single-digit. Why an ADC factory is really four factories, and the leverage that comes with being scarce.
Where It Chokes
The chain chokes at four nodes, and most firms hold only one. The payload layer is a single point of failure, and the buyers who could relieve the choke are walking away from it.
The Gap Quantified
The market does not disclose a kilogram shortfall, but it lets you bound the human one. Roughly 2,875 net-new specialist roles in the announced build-out, landing on a near-frictionless labour market.
The Real Bottleneck Is People
The constraint, named by the firms that profit from it. The pay gap that strands the scarce people away from the nodes that need them. Capacity now secured by buying people, not hiring them.
The Map Redrawn by Policy and Geography
BIOSECURE and the Section 232 proclamation. Why the tariff carve-out protects the finished molecule and leaves its offshore inputs exposed, concentrating pressure on the scarcest node.
The Competitive Field
The captive capitulation, the leverage it hands the capable few, and the foundational chemistry IP that forms the second moat. Who wins the next two years, and who is exposed.
What the Squeeze Means for Each Buyer
The read for developers, CDMOs, and investors, separately. What each one should do now, and what each is most likely to get wrong.
Outlook
Two clocks are running. The overbuild-then-retreat pattern to watch, the leading indicators that turn first, and the base case with its tell.
Free Preview
Read the Extract version first.
Announced ADC capacity versus the workforce to run it. ~2,875 net-new specialist roles announced, almost all dated 2029-2030, against a US life-sciences pool near full employment. One exhibit and the talent constraint underneath it, lifted from the full nine-section report.
No spam, no resale.
From the report
2,875
specialist ADC roles announced across the 2029 to 2030 build-out. Confirmable production hiring at those new sites: none.
A builder can cancel or write down a plant in a single quarter, and three captive build-outs already have. It cannot hire a containment-grade process team on the same timetable. Announced capacity and staffed capacity are not the same thing, and the gap between them is where the squeeze lives.
Who reads this and what they use it for
ADC developers
CMC and manufacturing leadership managing the real gating risk: manufacturing predictability and the specialist people who have to be seated years ahead of a filing, not the molecule.
CDMOs
Commercial and operations leadership. For the next two years the squeeze runs in your favour, and the order book proves it, if you can staff the lines.
Investors and corporate development
Capacity dated to 2029 and 2030 discounted for staffing risk and reversibility, and the upstream payload node priced as the real exposure the tariff carve-out leaves open.
Byron Fitzgerald, Founder, ProGen Search
About the Author
Byron Fitzgerald
Byron Fitzgerald has spent more than 15 years in life sciences executive search and founded ProGen Search in 2024. He is a three-time founder, having previously bootstrapped a specialist consultancy from a standing start to 36 consultants. He has placed VP to C-suite leadership across Quality, MSAT, Technical Operations, CMC, Manufacturing, Regulatory, and Business Development functions for organisations ranging from pre-clinical biotechs to multinational CDMOs and radiopharma developers. Through retained search and commissioned intelligence work, he speaks daily with the C-suite, investors, PE/VC partners, and BD leaders who set strategy across this sector.
His published market intelligence on radiopharmaceutical manufacturing, CDMO capacity constraints, ADC execution risk, and advanced modality talent markets is read by C-suite leaders, institutional investors, and board members globally.
Choose your access
Three tiers, calibrated to how you intend to use the work.
Individual
$1,495
Single reader. Personal use within one company.
- Single named reader licence
- Full PDF report (9 sections)
- The announced-versus-staffed capacity exhibit
- The four-node choke map
- Direct email access to Byron Fitzgerald for clarification questions
Enterprise
$5,995
Distribute across one operating company or strategy team.
- Full company licence covering all employees and majority-owned subsidiaries
- Full PDF report (9 sections)
- The announced-versus-staffed capacity exhibit
- The four-node choke map
- Internal redistribution rights (intranet, shared drives, board packs)
- Priority email access to Byron Fitzgerald
Need to pay by invoice or PO? Email byron.fitzgerald@progensearch.com.
Investor & Bank Licence
$14,995
Investment banks, institutional investors, and consulting firms citing the report in client materials.
- Full firm licence covering all investment professionals, analysts, and portfolio companies
- Full PDF report (9 sections)
- The announced-versus-staffed capacity exhibit
- The four-node choke map
- Use in investor memos, client deliverables, due diligence reports, and committee papers
- Citation rights in pitches, transaction memos, and fund communications
- Priority email access to Byron Fitzgerald
Need to pay by invoice or PO? Email byron.fitzgerald@progensearch.com.
By completing your purchase, you agree to our Purchase Terms.
Frequently asked questions
When do I get the report?
The report is published and delivered direct, by email, on completion of purchase.
What is the methodology and how is it sourced?
A single reconciled evidence base, collected and fact-checked across twelve evidence streams, then locked. Every figure traces to a data point marked verified, corrected, or conflict-resolved. Claims that could not be stood up are quarantined and kept out of every headline and exhibit. The central talent finding was built by cross-referencing every announced expansion against employer-confirmed hiring at that site.
How does this relate to The State of ADCs 2026?
The State of ADCs 2026 is the structural read of the whole sector, chemistry through capital. The ADC Supply Squeeze is the supply-side companion, focused on manufacturing capacity and the talent that gates it. They stand alone, and they read well together.
Free ADC intelligence
Read ADCs: The Chemical War Within and The $400M CMC Playbook in the Intelligence Vault. Visit Vault →
Ready when you are.
If you are choosing a manufacturing partner, planning capacity, or pricing an ADC asset in 2026, the bottleneck is no longer the chemistry. It is who can make it and who can staff it. This report maps both.
View pricingWant ongoing intelligence between flagship reports? ProGen Radar Pro - $99/month, 14-day guarantee. Learn more →